The cotransporter SGLT2 is responsible for 90% of renal glucose reabsorption, and we recently showed that MAP17 appears to work as a required β-subunit. We report in the present study a detailed functional characterization of human SGLT2 in coexpression with human MAP17 in Xenopus laevis oocytes. Addition of external glucose generates a large inward current in the presence of Na, confirming an electrogenic transport mechanism. At a membrane potential of −50 mV, SGLT2 affinity constants for glucose and Na are 3.4 ± 0.4 and 18 ± 6 mM, respectively. The change in the reversal potential of the cotransport current as a function of external glucose concentration clearly confirms a 1:1 Na-to-glucose transport stoichiometry. SGLT2 is selective for glucose and α-methylglucose but also transports, to a lesser extent, galactose and 3- O-methylglucose. SGLT2 can be inhibited in a competitive manner by phlorizin ( Ki = 31 ± 4 nM) and by dapagliflozin ( Ki = 0.75 ± 0.3 nM). Similarly to SGLT1, SGLT2 can be activated by Na, Li, and protons. Pre-steady-state currents for SGLT2 do exist but are small in amplitude and relatively fast (a time constant of ~2 ms). The leak current defined as the phlorizin-sensitive current in the absence of substrate was extremely small in the case of SGLT2. In summary, in comparison with SGLT1, SGLT2 has a lower affinity for glucose, a transport stoichiometry of 1:1, very small pre-steady-state and leak currents, a 10-fold higher affinity for phlorizin, and an affinity for dapagliflozin in the subnanomolar range.

The renal proximal tubule reabsorbs 90% of the filtered glucose load through the Na+-coupled glucose transporter SGLT2, and specific inhibitors of SGLT2 are now available to patients with diabetes to increase urinary glucose excretion. Using expression cloning, we identified an accessory protein, 17 kDa membrane-associated protein (MAP17), that increased SGLT2 activity in RNA-injected Xenopus oocytes by two orders of magnitude. Significant stimulation of SGLT2 activity also occurred in opossum kidney cells cotransfected with SGLT2 and MAP17. Notably, transfection with MAP17 did not change the quantity of SGLT2 protein at the cell surface in either cell type. To confirm the physiologic relevance of the MAP17-SGLT2 interaction, we studied a cohort of 60 individuals with familial renal glucosuria. One patient without any identifiable mutation in the SGLT2 coding gene (SLC5A2) displayed homozygosity for a splicing mutation (c.176+1G>A) in the MAP17 coding gene (PDZK1IP1). In the proximal tubule and in other tissues, MAP17 is known to interact with PDZK1, a scaffolding protein linked to other transporters, including Na+/H+ exchanger 3, and to signaling pathways, such as the A-kinase anchor protein 2/protein kinase A pathway. Thus, these results provide the basis for a more thorough characterization of SGLT2 which would include the possible effects of its inhibition on colocalized renal transporters.

Na-coupled cotransporters are proteins that use the trans-membrane electrochemical gradient of Na to activate the transport of a second solute. The sodium-glucose cotransporter 1 (SGLT1) constitutes a well-studied prototype of this transport mechanism but essential molecular characteristics, namely its quaternary structure and the exact arrangement of the C-terminal transmembrane segments, are still debated. After expression in Xenopus oocytes, human SGLT1 molecules (hSGLT1) were labelled on an externally accessible cysteine residue with a thiol-reactive fluorophore (tetramethylrhodamine-C5-maleimide, TMR). Addition of dipicrylamine (DPA, a negatively-charged amphiphatic fluorescence "quencher") to the fluorescently-labelled oocytes is used to quench the fluorescence originating from hSGLT1 in a voltage-dependent manner. Using this arrangement with a cysteine residue introduced at position 624 in the loop between transmembrane segments 12 and 13, the voltage-dependent fluorescence signal clearly indicated that this portion of the 12-13 loop is located on the external side of the membrane. As the 12-13 loop begins on the intracellular side of the membrane, this suggests that the 12-13 loop is re-entrant. Using fluorescence resonance energy transfer (FRET), we observed that different hSGLT1 molecules are within molecular distances from each other suggesting a multimeric complex arrangement. In agreement with this conclusion, a western blot analysis showed that hSGLT1 migrates as either a monomer or a dimer in reducing and non-reducing conditions, respectively. A systematic mutational study of endogenous cysteine residues in hSGLT1 showed that a disulfide bridge is formed between the C355 residues of two neighbouring hSGLT1 molecules. It is concluded that, 1) hSGLT1 is expressed as a disulfide bridged homodimer via C355 and that 2) a portion of the intracellular 12-13 loop is re-entrant and readily accessible from the extracellular milieu.

The Na+/glucose cotransporter SGLT2, which accounts for over 90% of renal glucose reabsorption, has become a major pharmaceutical target for type 2 diabetes treatment. Unfortunately, functional studies on SGLT2 have been hindered due to its lack of activity when expressed heterologously. Using an expression cloning strategy to identify a required accessory protein for SGLT2 function, we have identified MAP17 (membrane associated protein of 17 kDa) which is specifically expressed in the kidney proximal tubule, along with SGLT2. Using electrophysiology (oocytes) and radioactive uptakes (oocytes/OK cells), we demonstrate that MAP17 increases the activity of SGLT2 in both oocytes (150 fold) and OK cells (15 fold). Furthermore, Western blot and immunofluorescence studies using FLAG‐SGLT2 show that the cell surface density for SGLT2 is independent of MAP17 expression, which suggests that MAP17 stimulates the activity of SGLT2, but not its targeting. Finally, functional assays of disease‐causing mutations to SGLT2 (familial renal glucosuria) expressed in OK cells confirm these mutations to be non‐functional, even in the presence of MAP17. In conclusion, we have identified a cofactor responsible for the activation of SGLT2 which enables its characterization in heterologous systems.

Determining the structural characteristics of membrane transporters is essential to understanding their mechanisms. The sodium-glucose cotransporter 1 (SGLT1) has 14 transmembrane segments (TMs) and is a member of the LeuT structural family as demonstrated by the crystal structure of Vibrio SGLT. Despite numerous studies on SGLT1, its quaternary structure and the possibility of a re-entrant loop between TMs 12 and 13 (following LeuT numbering) are still uncertain. In this study, dipicrylamine (DPA), a lipophilic anion which distributes across the membrane according to the membrane potential, was used as a resonance-energy-transfer acceptor from donor molecules attached to SGLT1 via cysteine labelling. By randomly labelling SGLT1 C511 with Alexa 488-C5-maleimide and tetramethylrhodamine-C5-maleimide (TMR), we observed a clear DPA-sensitive FRET signal indicating molecular contact between SGLT1 monomers. Western blotting of myc-tagged SGLT1 in absence of the reducing agent β-mercaptoethanol revealed a 150 kDa band which disappeared in the presence of β-mercaptoethanol, leaving only a 75 kDa band as would be expected for monomeric SGLT1. Using a series of 18 mutants where individual cysteines were replaced by alanine, C355 was found to be responsible for the disulfide bridge that stabilizes SGLT1 dimers. We also investigated the loop between TMs 12 and 13 by measuring energy transfer between TMR-tagged SGLT1 E624C and DPA. We unambiguously found that this loop, which is poorly conserved in Vibrio SGLT and is assumed to be intracellular, lies significantly above the extracellular plane of the membrane. Taken together, these results establish structural characteristics of SGLT1 which could not be settled using the bacterial homolog structure.

We describe two siblings from a consanguineous family with autosomal recessive Fanconi's syndrome and hypophosphatemic rickets. Genetic analysis revealed a homozygous in-frame duplication of 21 bp in SLC34A1, which encodes the renal sodium-inorganic phosphate cotransporter NaPi-IIa, as the causative mutation. Functional studies in Xenopus laevis oocytes and in opossum kidney cells indicated complete loss of function of the mutant NaPi-IIa, resulting from failure of the transporter to reach the plasma membrane. These findings show that disruption of the human NaPi-IIa profoundly impairs overall renal phosphate reabsorption and proximal-tubule function and provide evidence of the critical role of NaPi-IIa in human renal phosphate handling.

SMCT1 is a Na-coupled cotransporter of short chain monocarboxylates, which is expressed in the apical membrane of diverse epithelia such as colon, renal cortex, and thyroid. We previously reported that SMCT1 cotransport was reduced by extracellular Cl(-) replacement with cyclamate(-) and that the protein exhibited an ostensible anionic leak current. In this paper, we have revisited the interaction between small monovalent anions and SMCT cotransport and leak currents. We found that the apparent Cl(-) dependence of cotransport was due to inhibition of this protein by the replacement anion cyclamate, whereas several other replacement anions function as substrates for SMCT1; a suitable replacement anion (MES(-)) was identified. The observed outward leak currents represented anionic influx and favored larger anions (NO(3)(-)>I(-)>Br(-)>Cl(-)); currents in excess of 1 muA (at +50 mV) could be observed and exhibited a quasilinear relationship with anion concentrations up to 100 mM. Application of 25 mM bicarbonate did not produce measurable leak currents. The leak current displayed outward rectification, which disappeared when external Na(+) was replaced by N-methyl-d-glucamine(+). More precisely, external Na(+) blocked the leak current in both directions, but its K(i) value rose rapidly when membrane potential became positive. Thus SMCT1 possesses a anionic leak current that becomes significant whenever external Na(+) concentration is reduced. The presence of this leak current may represent a second function for SMCT1 in addition to cotransporting short chain fatty acids, and future experiments will determine whether this function serves a physiological role in tissues where SMCT1 is expressed.

Expression of the Na(+)/glucose cotransporter SGLT1 in Xenopus oocytes is characterized by a phlorizin-sensitive leak current (in the absence of glucose) that was originally called a "Na(+) leak" and represents some 5-10% of the maximal Na(+)/glucose cotransport current. We analyzed the ionic nature of the leak current using a human SGLT1 mutant (C292A) displaying a threefold larger leak current while keeping a reversal potential (V(R)) of approximately -15 mV as observed for wt SGLT1. V(R) showed only a modest negative shift when extracellular Na(+) concentration ([Na(+)](o)) was lowered and it was completely insensitive to changes in extracellular Cl(-). When extracellular pH (pH(o)) was decreased from 7.5 to 6.5 and 5.5, V(R) shifted by +15 and +40 mV, respectively, indicating that protons may be the main charge carrier at low pH(o) but other ions must be involved at pH(o) 7.5. In the presence of 15 mM [Na(+)](o) (pH(o) = 7.5), addition of 75 mM of either Na(+), Li(+), Cs(+), or K(+) generated similar increases in the leak current amplitude. This observation, which was confirmed with wt SGLT1, indicates a separate pathway for the leak current with respect to the cotransport current. This means that, contrary to previous beliefs, the leak current cannot be accounted for by the translocation of the Na-loaded and glucose-free cotransporter. Using chemical modification and different SGLT1 mutants, a relationship was found between the cationic leak current and the passive water permeability suggesting that water and cations may share a common pathway through the cotransporter.

Myo‐inositol (Ins) is an essential component of phosphatidylinositol, polyphosphoinositides, and inositol polyphosphates including the second messenger, Ins‐1,4,5‐P3. Ins also serves as an organic osmolyte. Active transport of Ins from the extracellular environment is primarily dependent on the sodium/myo‐inositol cotransporter 1, SLC5A3 (SMIT1). To gain insight into the biological role of Ins, and of the SLC5A3 protein, we have generated a knock out mouse model. The Slc5a3 KO newborn mice die post partum, but can be rescued if the pregnant mother is treated with 1% Ins enriched water. Our results show that Ins levels increased in brain and whole KO fetuses following rescue with 1% Ins. Yet, the tissue PtdIns content was normal in the KO with or without Ins treatment. Most importantly, the expression of the mitochondrial ribosomal protein subunit 6 (Mrps6) gene, which shares exon 1 with the Slc5a3 gene, was also not aberrantly expressed in E18.5 KO fetal brain. With or without 1% Ins treatment, selective neuronal immunostaining was normal in the central and peripheral nervous system of E18.5 fetuses and in adult mice, who also had a normal complete necropsy. We conclude that the role of Ins in pathophysiology, and perhaps also in regulation of the SLc5a3/Mrps6 gene(s), which phylogenetically share genomic space since the appearance of vertebrates, requires better delineation, especially in fetal development.

Myo‐inositol (MI) uptakes in cells is essentially performed by two Na+‐coupled transport systems; SMIT1, a basolateral system inducible through hypertonicity and SMIT2, an apical system responsible for MI uptake in the kidney and intestine, amongst other tissues. In diabetes, urinary MI excretion is increased by 1 order of magnitude through a non‐established mechanism. The purpose of this study is thus to investigate the influence of an acute diabetic condition (5‐day streptozotocintreatment) on the expression of both SMIT mRNA's in rat brain, liver, muscle, kidney and intestine through quantitative‐RT‐PCR (qRT‐PCR). Also, SMIT2 activity was determined by measuring MI transport in purified brush border membranes (BBMv) from kidney and intestine. SMIT1 transcripts are mainly found in the kidney where it doubles in diabetic rats. Other tissues show more modest mRNA levels and were not altered in diabetes. SMIT2 transcripts were found in all tested tissues in varying levels but were not modified in diabetes. MI uptakes performed on kidney and intestine BBMv confirmed the qRT‐PCR results showing no variations of transport in STZ rats due to SMIT2. We thus conclude that the increase in MI urinary excretion is not due to a reduction in the apical expression of MI cotransporter SMIT2.

Ablation of the murine Slc5a3 gene results in severe myo-inositol (Ins) deficiency and congenital central apnea due to abnormal respiratory rhythmogenesis. The lethal knockout phenotype may be rescued by supplementing the maternal drinking water with 1% Ins. In order to test the hypothesis that Ins deficiency leads to inositide deficiencies, which are corrected by prenatal treatment, we measured the effects of Ins rescue on Ins, phosphatidylinositol (PtdIns) and myo-inositol polyphosphate levels in brains of E18.5 knockout fetuses. As the Slc5a3 gene structure is unique in the sodium/solute cotransporter (SLC5) family, and exon 1 is shared with the mitochondrial ribosomal protein subunit 6 (Mrps6) gene, we also sought to determine whether expression of its cognate Mrps6 gene is abnormal in knockout fetuses. The mean level of Ins was increased by 92% in brains of rescued Slc5a3 knockout fetuses (0.48 versus 0.25 nmol/mg), but was still greatly reduced in comparison to wildtype (6.97 nmol/mg). The PtdIns, InsP(5) and InsP(6) levels were normal without treatment. Mrps6 gene expression was unaffected in the E18.5 knockout fetuses. This enigmatic model is not associated with neonatal PtdIns deficiency and rescue of the phenotype may be accomplished without restoration of Ins. The biochemical mechanism that both uniformly leads to death and allows for Ins rescue remains unknown. In conclusion, in neonatal brain tissue, Mrps6 gene expression may not be contingent on function of its embedded Slc5a3 gene, while inositide deficiency may not be the mechanism of lethal apnea in null Slc5a3 mice.

This study presents the characterization of MI uptake in rat intestine using purified membrane preparations (BBMv). The two Na+‐coupled myo‐inositol (MI) cotransporters identified (SMIT1 and SMIT2) can be differentiated through inhibition studies using the selective substrates D‐chiro‐inositol (DCI, specific for SMIT2) and L‐fucose (specific for SMIT1). Results show that SMIT2 is exclusively responsible for apical MI transport in rat intestine. Other sugar transport systems present in apical membranes (SGLT1 and GLUT5) lacked any significant contribution to MI uptake. Functional analysis of rat SMIT2 activity determined using electrophysiological studies in Xenopus oocytes, demonstrated similarities to the activities of SMIT2 from species (rabbit and human), displaying high affinities for MI (0.150 ± 0.040 mM), DCI (0.31 ± 0.06 mM) and Pz (0.016 ± 0.007 mM), low affinity for glucose (36 ± 7 mM) and no affinity for L‐fucose. Electrophysiological studies essentially confirmed those found in rat intestinal BBMv with exception of glucose affinity which was about 40‐fold higher in vesicles (Ki = 0.94 ± 0.35 mM) when compared to oocytes. Finally, GLUT2 expressed in oocytes did not mediate any significant radiolabelled MI uptake, indicating that this transport system does not participate in the basolateral exit of MI from small intestine.

Myo-inositol (MI) is a compatible osmolyte used by cells to compensate for changes in the osmolarity of their surrounding milieu. In kidney, the basolateral Na + -MI cotransporter (SMIT1) and apical SMIT2 proteins are homologous cotransporters responsible for cellular uptake of MI. It has been shown in the Madin-Darby canine kidney (MDCK) cell line that SMIT1 expression was under the control of the tonicity-sensitive transcription factor, tonicity-responsive enhancer binding protein (TonEBP). We used an MDCK cell line stably transfected with SMIT2 to determine whether variations in external osmolarity could also affect SMIT2 function. Hyperosmotic conditions (+200 mosM raffinose or NaCl but not urea) generated an increase in SMIT2-specific MI uptake by three- to ninefold in a process that required protein synthesis. Using quantitative RT-PCR, we have determined that hyperosmotic conditions augment both the endogenous SMIT1 and the transfected SMIT2 mRNAs. Transport activities for both SMIT1 and SMIT2 exhibited differences in their respective induction profiles for both their sensitivities to raffinose, as well as in their time course of induction. Application of MG-132, which inhibits nuclear translocation of TonEBP, showed that the effect of osmolarity on transfected SMIT2 was unrelated to TonEBP, unlike the effect observed with SMIT1. Inhibition studies involving the hyperosmolarity-related MAPK suggested that p38 and JNK play a role in the induction of SMIT2. Further studies have shown that hyperosmolarity also upregulates another transfected transporter (Na + -glucose), as well as several endogenously expressed transport systems. This study shows that hyperosmolarity can stimulate transport in a TonEBP-independent manner by increasing the amount of mRNA derived from an exogenous DNA segment.

Several different stoichiometries have been proposed for the Na(+)/monocarboxylate cotransporter SMCT1, including variable Na(+)/substrate stoichiometry. In this work, we have definitively established an invariant 2:1 cotransport stoichiometry for SMCT1. By using two independent means of assay, we first showed that SMCT1 exhibits a 2:1 stoichiometry for Na(+)/lactate cotransport. Radiolabel uptake experiments proved that, unlike lactate, propionic acid diffuses passively through oocyte membranes and, consequently, propionate is a poor candidate for stoichiometric determination by these methods. Although we previously determined SMCT1 stoichiometry by measuring reversal potentials, this technique produced erroneous values, because SMCT1 simultaneously mediates both an inwardly rectifying cotransport current and an outwardly rectifying anionic leak current; the leak current predominates in the range where reversal potentials are observed. We therefore employed a method that compared the effect of halving the external Na(+) concentration to the effect of halving the external substrate concentration on zero-current potentials. Both lactate and propionate were cotransported through SMCT1 using 2:1 stoichiometries. The leak current passing through the protein has a 1 osmolyte/charge stoichiometry. Identification of cotransporter stoichiometry is not always a trivial task and it can lead to a much better understanding of the transport activity mediated by the protein in question.

SMCT1 is encoded by the SLC5A8 gene, which is inactivated by methylation in colon, brain and thyroid cancer. SMCT1 cotransports Na+ with different monocarboxylates containing 3 to 8 carbon atoms but the transport properties discovered so far are insufficient to explain the putative role played by SMCT1 in cell proliferation. Three different stoichioimetries have been published for the cotransport passing through SMCT1, including a claim for different stoichiometries when lactate and propionate are cotransported. Electrophysiological analysis of this cotransporter is impeded by the presence of an anionic leak with the following selectivity (NO3−> I−>Br−>Cl−). We have established a 2:1 stoichiometry for lactate cotransport by use of three independent techniques: one method combined radiolabel uptake with current measurements, another combined radiolabel uptake with volume measurements and a third compared membrane potential changes in response to altered external substrate concentrations. We showed that the first two methods are unsuitable for measuring stoichiometry of propionate, which diffuses readily across the membrane. The third method is unaffected by passive diffusion of propionate and established a constant, 2:1 stoichiometry through this protein for both lactate and propionate. Volume measurement during the stimulation of a NO3− leak indicates a simple influx of inorganic anions which appears unaffected by the presence of substrate. In conclusion, SMCT1 exhibits a 2:1 stoichiometry which coexists with an anionic leak current.

The HIV-1 encoded accessory protein, viral protein R (Vpr) is responsible for several biological effects in HIV-1-infected cells including nuclear transport of the preintegration complex, activation of long terminal repeat (LTR)-mediated transcription, and the induction of cell-cycle arrest and apoptosis. Vpr's ability to arrest cells at the G2 phase of the cell cycle is due to the inactivation of p34(cdc2) cyclin B complex, resulting in hypophosphorylation of substrates involved in cell-cycle progression from G2 to mitosis (M). Poly(A) polymerase (PAP), the enzyme responsible for poly(A) addition to primary transcripts, contains multiple consensus phosphorylation sites for p34(cdc2) cyclin B kinase that regulates its catalytic activity. We investigated the effects of Vpr on the activity of PAP in Jurkat cells using a superinfection system. Superinfection of cells using Vpr+ vesicular stomatitis virus G protein (VSV-G)-pseudotyped virus caused a complete dephosphorylation of PAP. Cotransfection studies in 293T cells and Xenopus oocyte RNA injection experiments mirrored these effects. Vpr's dramatic effect on PAP dephosphorylation was reflected in enhanced polyadenylation activity in PAP activity assays. HIV-1 Vpr appears to enhance processes that are coupled to transcription such as polyadenylation and could ultimately prove to optimize HIV-1 replication and contribute to HIV-1 pathogenesis. (C)2002 Elsevier Science.